The obective of the EXPLORE Xa study was to assess the safety and tolerability of betrixaban at doses of 40 mg, 60 mg and 80 mg given orally once a day for at least 3 months compared to dose-adjusted warfarin in patients with non-valvular atrial fibrillation (AF).

Primary endpoint:

The time to occurrence of majoror clinically relevant non-major bleeding.

Secondary endpoints:

The time to occurrence of any bleeding (including major, clinically relevant non-major, and minimal) and the time to occurrence of death, ischemic or nonischemic stroke, MI, or other systemic embolism.

Study Type

Interventional - Drug

Study Design

Randomized, parallel group design, multicenter, active comparator, dose-finding

NO. of Countries


NO. of Sites


NO. of Participants


Study Period

2008 - 2010


Portola Pharmaceuticals

Back To Top